
a
RTK/RAS/PI(3)K signalling altered in 88%
EGFR
ERBB2
PDGFRA
MET
Mutation, amplification in 45%
Mutation in 8%
Amplification in 13%
Amplification in 4%
Mutation, homozygous deletion in 18%
NF1
RAS
Mutation in 2%
PI(3)K
Mutation in 15%
PTEN
Mutation, homozygous deletion in 36%
AKT
Amplification in 2%
Proliferation survival translation
FOXO
Mutation in 1%
b
p53 signalling altered in 87%
Activated oncogenes
CDKN2A (ARF)
Homozygous deletion, mutation in 49%
Amplification in 14%
MDM2
MDM4
Amplification in 7%
TP53
Mutation, homozygous deletion in 35%
Senescence
Apoptosis
c
CDKN2A (P16/INK4A)
CDKN2B
CDKN2C
Homozygous deletion, mutation in 52%
Homozygous deletion in 47%
Homozygous deletion in 2%
Amplification in 18%
Amplification in 2%
Amplification in 1%
CDK4
CCND2
CDK6
Homozygous deletion, mutation in 11%
RB1
G1/S progression
RB signalling altered in 78%